02.22.19
Emergex Vaccines has secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire in the UK.
In addition, the company has appointed Phillip Williams as chief scientific officer, who will lead the company’s R&D operations on site. A nanotechnology expert, Dr. Williams has extensive experience in the field of gold nanoparticle development and has been involved in the production and validation of the world’s first up-scaling methodologies for nanoparticles of this nature. Prior to this appointment he was principle scientist at Midatech Pharma.
The Milton Park facility provides Emergex with its own fully equipped and resourced in-house R&D capabilities. This gives the company overall internal control of all its vaccine development programs.
“On behalf of the management team, I would like to welcome Phil and our newly appointed team of scientists to Emergex,” said Storme Moore-Thornicroft, co-founder and chief operating officer, Emergex. “We are looking forward to working together to effectively progress our vaccine candidates through the development pathway. These appointments, along with securing and further enhancing our own operational capability via this new facility, represent a real and significant milestone in the evolution and growth of our business.”
In addition, the company has appointed Phillip Williams as chief scientific officer, who will lead the company’s R&D operations on site. A nanotechnology expert, Dr. Williams has extensive experience in the field of gold nanoparticle development and has been involved in the production and validation of the world’s first up-scaling methodologies for nanoparticles of this nature. Prior to this appointment he was principle scientist at Midatech Pharma.
The Milton Park facility provides Emergex with its own fully equipped and resourced in-house R&D capabilities. This gives the company overall internal control of all its vaccine development programs.
“On behalf of the management team, I would like to welcome Phil and our newly appointed team of scientists to Emergex,” said Storme Moore-Thornicroft, co-founder and chief operating officer, Emergex. “We are looking forward to working together to effectively progress our vaccine candidates through the development pathway. These appointments, along with securing and further enhancing our own operational capability via this new facility, represent a real and significant milestone in the evolution and growth of our business.”
